Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
AI tool automates liver tumor detection and monitoring
2.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
3.
For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.
4.
Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.
5.
Overdosing on Chemotherapy: A Single Gene Test Could Prevent Hundreds of Deaths Annually.
1.
The Lung Cancer Shift: From Reactive Treatment to Proactive Precision Medicine
2.
Colorectal Cancer Uncovered: CME, Case Studies, and Clinical Strategies
3.
An Analytical and Statistical Journey through Genomic Revolution, Novel Therapeutics, and Future Horizons in Lymphoma 2025
4.
A Comprehensive Guide To Understanding Plasma Osmolality
5.
Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
3.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge